
Vertex Pharmaceuticals company profile
$538.60−0.74%Close 13 Nov 2026
About Vertex Pharmaceuticals
Vertex Pharmaceuticals is a global biotechnology company that discovers, develops, and commercializes medicines for serious diseases, with a focus on specialty markets. Its approved products treat cystic fibrosis, with five CFTR modulator medicines marketed in more than 60 countries; severe sickle cell disease and transfusion dependent beta thalassemia, through the gene-editing therapy CASGEVY, available in the U.S., Europe, Canada, and the Middle East; and acute pain, through JOURNAVX, approved in the U.S. The company sells primarily to specialty pharmacies and distributors, major U.S. wholesalers, and hospitals and clinics outside the U.S., and promotes its medicines directly to healthcare professionals. Its clinical pipeline includes programs in kidney diseases, type 1 diabetes, neuropathic pain, and myotonic dystrophy type 1.
A summary of the business section of the company's latest annual report, filed 13 Feb 2026.
Company facts
| Ticker | VRTX · Nasdaq |
|---|
| Sector | Pharmaceuticals |
|---|
| Industry | Biotechnology |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 875320 |
|---|
| Latest annual report | 10-K, filed 13 Feb 2026 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| Bruce I. Sachs | Director | 94.5K · < 1% | Gift, 27 Aug 2026 |
|---|
| Stuart A. Arbuckle | EVP, COO | 68.5K · < 1% | Shares withheld for tax, 1 Jul 2025 |
|---|
| Amit Sachdev | EVP Chief Patient & Ext Af Off | 48.5K · < 1% | Grant or award, 21 Jul 2026 |
|---|
| Reshma Kewalramani | CEO & President · Director | 47.8K · < 1% | Sale under a 10b5-1 plan, 6 Nov 2026 |
|---|
| Alan Garber | Director | 37.6K · < 1% | Grant or award, 1 May 2026 |
|---|
| Jeffrey M. Leiden | Executive Chairman · Director | 35.2K · < 1% | Shares withheld for tax, 24 Feb 2026 |
|---|
| Charles F. Wagner, Jr. | EVP, CO & FO | 27.7K · < 1% | Shares withheld for tax, 24 Feb 2026 |
|---|
| Carmen Bozic | EVP and CMO | 25.5K · < 1% | Sale under a 10b5-1 plan, 26 Jun 2026 |
|---|
| Diana McKenzie | Director | 9.4K · < 1% | Disposition to the issuer, 1 May 2026 |
|---|
| Lloyd Carney | Director | 6.3K · < 1% | Gift, 19 Nov 2025 |
|---|
| Suketu Upadhyay | Director | 5.1K · < 1% | Disposition to the issuer, 1 May 2026 |
|---|
| Nancy Thornberry | Director | 4.8K · < 1% | Grant or award, 1 May 2026 |
|---|
| Sangeeta N. Bhatia | Director | 4.3K · < 1% | Sale under a 10b5-1 plan, 4 May 2026 |
|---|
| Jennifer Schneider | Director | 1.7K · < 1% | Disposition to the issuer, 1 May 2026 |
|---|
| Brennan Daniel J. | Director | — | Grant or award, 20 Oct 2026 |
|---|
| van Grunsven Jasper | EVP, CP and NPPO | — | Grant or award, 8 Sep 2026 |
|---|
| Ambrose Kristen | SVP & Chief Accounting Officer | — | Grant or award, 28 Aug 2026 |
|---|
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. | — | Grant or award, 21 Jul 2026 |
|---|
| McKechnie Duncan | EVP, Chief Commercial Officer | — | Sale under a 10b5-1 plan, 2 Jul 2026 |
|---|
| Liu Joy | EVP and Chief Legal Officer | — | Sale under a 10b5-1 plan, 1 Jul 2026 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
VRTX in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.